SILEXION THERAPEUTICS CORP APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
SILEXION THERAPEUTICS CORP (SLXN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $134.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-03-17
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $38.00K.
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $38.00K, a 99.34% decline year-over-year.
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $37.00K, a 15.63% increase year-over-year.
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $21.00K, a 34.38% decline year-over-year.
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $134.00K, a 97.71% decline from fiscal 2024.
- SILEXION THERAPEUTICS CORP apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $5.86M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $76.00K derived: sum of 2 quarters · filed 2026-03-17 | $113.00K derived: sum of 3 quarters · filed 2026-03-17 | $134.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $38.00K 10-Q · filed 2025-11-12 | $75.00K derived: sum of 2 quarters · filed 2025-11-12 | $96.00K 10-Q · filed 2025-11-12 | $96.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $37.00K 10-Q · filed 2025-08-12 | $58.00K 10-Q · filed 2025-08-12 | $58.00K derived: sum of 3 quarters · filed 2026-03-17 | $5.86M derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $21.00K 10-Q · filed 2025-05-13 | $21.00K derived: sum of 2 quarters · filed 2026-03-17 | $5.82M derived: sum of 3 quarters · filed 2026-03-17 | $5.85M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.80M derived: sum of 2 quarters · filed 2026-03-17 | $5.83M derived: sum of 3 quarters · filed 2026-03-17 | $5.86M 10-K · filed 2026-03-17 |
| 2024-09-30 | $5.80M 10-Q · filed 2025-11-12 | $5.83M derived: sum of 2 quarters · filed 2025-11-12 | $5.86M 10-Q · filed 2025-11-12 | $5.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $32.00K 10-Q · filed 2025-08-12 | $64.00K 10-Q · filed 2025-08-12 | $98.00K derived: sum of 3 quarters · filed 2025-08-20 | $130.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $32.00K 10-Q · filed 2025-05-13 | $66.00K derived: sum of 2 quarters · filed 2025-08-20 | $98.00K derived: sum of 3 quarters · filed 2025-08-20 | $130.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $34.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $66.00K derived: sum of 2 quarters · filed 2025-08-20 | $98.00K derived: sum of 3 quarters · filed 2025-08-20 | $130.00K 8-K · filed 2025-08-20 |
| 2023-09-30 | $32.00K 10-Q · filed 2024-11-14 | $64.00K derived: sum of 2 quarters · filed 2024-11-14 | $96.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $32.00K 10-Q · filed 2024-08-29 | $64.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |